<!DOCTYPE html><html><head><meta charset="utf-8"></meta><meta name="viewport" content="width=device-width" initial-scale="1"></meta><style>
      /* Create a running element */
      #header-and-footer {
        position: running(header-and-footer);
        text-align: right;
      }

      /* Add that running element to the top and bottom of every page */
      @page {
        @top {
          content: element(header-and-footer);
        }
        @bottom {
          content: element(header-and-footer);
        }
      }

      /* Add a page number */
      #page-number {
        content: "Page " counter(page);
      }

      @page { size: A4 }

      /* Create a title page with a full-bleed background and no header */
      /* Create a soa page with landscape orientation */
      #title-page {
        page: title-page;
      }
      .soa-page {
        page: soa-page
      }

      @page title-page {
        @top {
          content: "";
        }
      }

      @page soa-page {
        size: A4 landscape
      }

      #title-page h1 {
        padding: 200px 0 40px 0;
        font-size: 30px;
      }

      /* Dynamically create a table of contents with leaders */
      #table-of-contents a {
        content: target-content(attr(href)) leader('.') target-counter(attr(href), page);
        color: #000000;
        text-decoration: none;
        display: block;
        padding-top: 5px;
      }

      /* Float the footnote to a footnotes area on the page */
      .footnote {
        float: footnote;
        font-size: small;
      }

      .page {
        page-break-after: always;
      }

      body {
        counter-reset: chapter;
        font-family: 'Times New Roman';
        color: #000000;
      }

      .usdm-warning {
        font-style: italic;
        color: red;
      }

      .soa-body-text {
        font-size: 10px;
        text-align: center
      }

      .soa-activity-text {
        font-size: 10px;
        text-align: left
      }

    </style><link href="https://fonts.googleapis.com/css2?family=Open+Sans:wght@400;600;800&amp;display=swap" rel="stylesheet"></link><link href="https://cdn.jsdelivr.net/npm/bootstrap@5.3.2/dist/css/bootstrap.min.css" rel="stylesheet" integrity="sha384-T3c6CoIi6uLrA9TneNEoa7RxnatzjcDSCmG1MXxSR1GAsXEV/Dwwykc2MPK8M2HN" crossorigin="anonymous"></link></head><body>
      <div id="title-page" class="page">
        <div class="container">
          <div class="row">
            <div class="col-md-8 offset-md-2 text-center">
              <h1>Xanomeline (LY246708)</h1>
            </div>
          </div>
          <div class="row mt-5">
            <div class="col-md-8 offset-md-2 text-center">
              <p class="usdm-warning">Note:</p>
              <p class="usdm-warning">This document is generated from content held within the Unified Studies Definitions Model. It is for test purposes only.</p>
            </div>
          </div>
        </div>
        <div id="header-and-footer">
          <span id="page-number"></span>
        </div>
      </div>
    <div class="page"><div><table><tr><th style="vertical-align: top; text-align: left"><p>Sponsor Confidentiality Statement:</p></th><td style="vertical-align: top; text-align: left"><p></p></td></tr><tr><th style="vertical-align: top; text-align: left"><p>Full Title:</p></th><td style="vertical-align: top; text-align: left"><p>Safety and Efficacy of the Xanomeline Transdermal Therapeutic System (TTS) in Patients with Mild to Moderate Alzheimer's Disease</p></td></tr><tr><th style="vertical-align: top; text-align: left"><p>Trial Acronym:</p></th><td style="vertical-align: top; text-align: left"><p>LZZT</p></td></tr><tr><th style="vertical-align: top; text-align: left"><p>Protocol Identifier:</p></th><td style="vertical-align: top; text-align: left"><p>H2Q-MC-LZZT</p></td></tr><tr><th style="vertical-align: top; text-align: left"><p>Original Protocol:</p></th><td style="vertical-align: top; text-align: left"><p></p></td></tr><tr><th style="vertical-align: top; text-align: left"><p>Version Number:</p></th><td style="vertical-align: top; text-align: left"><p>2</p></td></tr><tr><th style="vertical-align: top; text-align: left"><p>Version Date:</p></th><td style="vertical-align: top; text-align: left"><p>2006-07-01</p></td></tr><tr><th style="vertical-align: top; text-align: left"><p>Amendment Identifier:</p></th><td style="vertical-align: top; text-align: left"><p>1</p></td></tr><tr><th style="vertical-align: top; text-align: left"><p>Amendment Scope:</p></th><td style="vertical-align: top; text-align: left"><p>Europe</p></td></tr><tr><th style="vertical-align: top; text-align: left"><p>Compound Codes(s):</p></th><td style="vertical-align: top; text-align: left"><p></p></td></tr><tr><th style="vertical-align: top; text-align: left"><p>Compound Name(s):</p></th><td style="vertical-align: top; text-align: left"><p></p></td></tr><tr><th style="vertical-align: top; text-align: left"><p>Trial Phase:</p></th><td style="vertical-align: top; text-align: left"><p>Phase II Trial</p></td></tr><tr><th style="vertical-align: top; text-align: left"><p>Short Title:</p></th><td style="vertical-align: top; text-align: left"><p>Xanomeline (LY246708)</p></td></tr><tr><th style="vertical-align: top; text-align: left"><p>Sponsor Name and Address:</p></th><td style="vertical-align: top; text-align: left"><p>Eli Lilly, Lilly Corporate Ctr,  Indianapolis  IN  4628 Denmark</p></td></tr><tr><th style="vertical-align: top; text-align: left"><p>Regulatory Agency Identifier Number(s):</p></th><td style="vertical-align: top; text-align: left"><p>NCT12345678</p></td></tr><tr><th style="vertical-align: top; text-align: left"><p>Spondor Approval Date:</p></th><td style="vertical-align: top; text-align: left"><p>2006-06-01</p></td></tr></table></div></div><div class="page">
      <div id="toc-page" class="page">
        <div id="table-of-contents">
          <a href="#section-1"></a><a href="#section-2"></a><a href="#section-3"></a><a href="#section-4"></a><a href="#section-5"></a><a href="#section-6"></a><a href="#section-7"></a><a href="#section-8"></a><a href="#section-9"></a><a href="#section-10"></a><a href="#section-11"></a><a href="#section-12"></a><a href="#section-13"></a><a href="#section-14"></a><a href="#section-15"></a>
        </div>
        <div align="center">
          <br/>
          <p class="usdm-warning">Note:</p>
          <p class="usdm-warning">The table of contents is auto generated upon PDF production and only includes first level sections.</p>
        </div>
        <div id="header-and-footer">
          <span id="page-number"></span>
        </div>
      </div>
    </div><div class="page"><h1 id="section-1">1 PROTOCOL SUMMARY</h1><div></div><div class=""><h2 id="section-1.1">1.1 Protocol Synopsis</h2><div></div></div><div class=""><h2 id="section-1.2">1.2 Trial Schema</h2><div></div></div><div class=""><h2 id="section-1.3">1.3 Schedule of Activities</h2><div></div></div></div><div class="page"><h1 id="section-2">2 INTRODUCTION</h1><div></div><div class=""><h2 id="section-2.1">2.1 Purpose of Trial</h2><div></div></div><div class=""><h2 id="section-2.2">2.2 Summary of Benefits and Risks</h2><div></div></div></div><div class="page"><h1 id="section-3">3 TRIAL OBJECTIVES, ENDPOINTS AND ESTIMANDS</h1><div></div><div class=""><h2 id="section-3.1">3.1 Primary Objectives</h2><div><table><tr><td style="vertical-align: top; text-align: left"><p>To determine if there is a statistically significant relationship (overall Type 1 erroralpha=0.05) between the change in both the ADAS-Cog (11) and CIBIC+ scores, and drug dose (0, 50 cm2 [54 mg], and 75 cm2 [81 mg]).</p></td><td style="vertical-align: top; text-align: left"><p>Alzheimer's Disease Assessment Scale - Cognitive Subscale, total of 11 items [ADAS-Cog (11)] at Week 24</p><p>Video-referenced Clinician’s Interview-based Impression of Change (CIBIC+) at Week 24</p></td></tr><tr><td style="vertical-align: top; text-align: left"><p>To document the safety profile of the xanomeline TTS.</p></td><td style="vertical-align: top; text-align: left"><p>Adverse events</p><p>Vital signs (weight, standing and supine blood pressure, heart rate)</p><p>Laboratory evaluations (Change from Baseline)</p></td></tr><tr><td style="vertical-align: top; text-align: left"><p>To assess the dose-dependent improvement in behavior. Improved scores on the Revised Neuropsychiatric Inventory (NPI-X) will indicate improvement in these
areas.</p></td><td style="vertical-align: top; text-align: left"><p>Alzheimer's Disease Assessment Scale - Cognitive Subscale, total of 11 items [ADAS-Cog (11)] at Weeks 8 and 16</p><p>Video-referenced Clinician’s Interview-based Impression of Change (CIBIC+) at Weeks 8 and 16</p><p>Mean Revised Neuropsychiatric Inventory (NPI-X) from Week 4 to Week 24</p></td></tr><tr><td style="vertical-align: top; text-align: left"><p>To assess the dose-dependent improvements in activities of daily living. Improved scores on the Disability Assessment for Dementia (DAD) will indicate improvement in these areas (see Attachment LZZT.5).</p></td><td style="vertical-align: top; text-align: left"></td></tr><tr><td style="vertical-align: top; text-align: left"><p>To assess the dose-dependent improvements in an extended assessment of cognition that integrates attention/concentration tasks. The Alzheimer's Disease Assessment Scale-14 item Cognitive Subscale, hereafter referred to as ADAS-Cog (14), will be used for this assessment (see Attachment LZZT.2).</p></td><td style="vertical-align: top; text-align: left"></td></tr><tr><td style="vertical-align: top; text-align: left"><p>To assess the treatment response as a function of Apo E genotype.</p></td><td style="vertical-align: top; text-align: left"></td></tr></table></div></div></div><div class="page"><h1 id="section-4">4 TRIAL DESIGN</h1><div></div><div class=""><h2 id="section-4.1">4.1 Description of Trial Design</h2><div></div><div class=""><h3 id="section-4.1.1">4.1.1 Participant Input into Design</h3><div></div></div></div><div class=""><h2 id="section-4.2">4.2 Rationale for Trial Design</h2><div><p>Previous studies of the oral formulation have shown that xanomeline tartrate may improve behavior and cognition. Effects on behavior are manifest within 2 to 4 weeks of initiation of treatment. The same studies have shown that 8 to 12 weeks are required to demonstrate effects on cognition and clinical global assessment. This study is intended to determine the acute and chronic effects of the TTS formulation in AD; for that reason, the study is of 26 weeks duration. Dosage specification has been made on the basis of tolerance to the xanomeline TTS in a clinical pharmacology study (H2Q-EW-LKAA), and target plasma levels as determined in studies of the oral formulation of xanomeline (H2Q-MC-LZZA).</p></div><div class=""><h3 id="section-4.2.1">4.2.1 Rationale for Comparator</h3><div><p>The parallel dosing regimen maximizes the ability to make direct comparisons between the treatment groups. The use of placebo allows for a blinded, thus minimally biased, study. The placebo treatment group is a comparator group for efficacy and safety assessment.</p><p>Two interim analyses are planned for this study. The first interim analysis will occur when 50% of the patients have completed Visit 8 (8 weeks). If required, the second interim analysis will occur when 50% of the patients have completed Visit 12 (24 weeks).</p></div></div><div class=""><h3 id="section-4.2.2">4.2.2 Rationale for Adaptive or Novel Trial Design</h3><div></div></div><div class=""><h3 id="section-4.2.3">4.2.3 Other Trial Design Considerations</h3><div></div></div></div><div class=""><h2 id="section-4.3">4.3 Access to Trial Intervention After End of Trial</h2><div></div></div><div class=""><h2 id="section-4.4">4.4 Start of Trial and End of Trial</h2><div></div></div></div><div class="page"><h1 id="section-5">5 TRIAL POPULATION</h1><div></div><div class=""><h2 id="section-5.1">5.1 Selection of Trial Population</h2><div><p>For Lilly studies, the following definitions are used:</p>
<div>
<div><strong>Screen</strong></div>
<div>
<p>Screening is the act of determining if an individual meets minimum requirements to become part of a pool of potential candidates for participation in a clinical study.</p>
<p>In this study, <strong>screening</strong> will include asking the candidate preliminary questions (such as age and general health status) and conducting invasive or diagnostic procedures and/or tests (for example, diagnostic psychological tests, x-rays, blood draws). Patients will sign the consent at their screening visit, thereby consenting to undergo the screening procedures and to participate in the study if they qualify.</p>
</div>
</div>
<div>
<div>To <strong>enter</strong></div>
<div>
<p>Patients <strong>entered</strong> into the study are those from whom informed consent for the study has been obtained. Adverse events will be reported for each patient who has <strong>entered</strong> the study, even if the patient is never assigned to a treatment group (<strong>enrolled</strong>).</p></div>
</div>
</div>
<div>
<div>To <strong>enroll</strong></div>
<div>
<p>Patients who are enrolled in the study are those who have been assigned to a treatment group. Patients who are entered into the study but fail to meet criteria specified in the protocol for treatment assignment will not be enrolled in the study.</p></div>
</div>
<p>At Visit 1, patients who meet the enrollment criteria of Mini-Mental State Examination (MMSE) score of 10 to 23 (Attachment LZZT.6), Hachinski Ischemia Score ≤4 (Attachment LZZT.8), a physical exam, safety labs, ECG, and urinalysis, will proceed to Visit 2 and Visit 3. At Visit 3, patients whose CNS imaging and other pending labs from Visit 1 satisfy the inclusion criteria (Section 3.4.2.1) will be enrolled in the study. Approximately 300 patients with a diagnosis of probable mild to moderate AD will be enrolled in the study.</p></div><div class=""><h2 id="section-5.2">5.2 Rationale for Trial Population</h2><div></div></div><div class=""><h2 id="section-5.3">5.3 Inclusion Criteria</h2><div><p>Patients may be included in the study only if they meet <strong>all</strong> the following criteria:</p><table><tr><td style="vertical-align: top; text-align: left"><p>01</p></td><td style="vertical-align: top; text-align: left"><p><p>Males and postmenopausal females at least 50 years of age.</p></p></td></tr><tr><td style="vertical-align: top; text-align: left"><p>02</p></td><td style="vertical-align: top; text-align: left"><p><p>Diagnosis of probable AD as defined by National Institute of Neurological and Communicative Disorders and Stroke (NINCDS) and the Alzheimer's Disease and Related Disorders Association (ADRDA) guidelines (Attachment LZZT.7).</p></p></td></tr><tr><td style="vertical-align: top; text-align: left"><p>03</p></td><td style="vertical-align: top; text-align: left"><p><p>MMSE score of 10 to 23.</p></p></td></tr><tr><td style="vertical-align: top; text-align: left"><p>04</p></td><td style="vertical-align: top; text-align: left"><p><p>Hachinski Ischemic Scale score of ≤4 (Attachment LZZT.8).</p></p></td></tr><tr><td style="vertical-align: top; text-align: left"><p>05</p></td><td style="vertical-align: top; text-align: left"><p><p>CNS imaging (CT scan or MRI of brain) compatible with AD within past 1 year.</p>
<p>The following findings are incompatible with AD:</p>
<ol type="a">
<li>
<p>Large vessel strokes</p>
<ol>
<li><p>Any definite area of encephalomalacia consistent with ischemic necrosis in any cerebral artery territory.</p></li>
<li><p>Large, confluent areas of encephalomalacia in parieto-occipital or frontal regions consistent with watershed infarcts.</p></li>
<p>The above are exclusionary. Exceptions are made for small areas of cortical asymmetry which may represent a small cortical stroke or a focal area of atrophy provided there is no abnormal signal intensity in the immediately underlying parenchyma. Only one such questionable area allowed per scan, and size is restricted to ≤1cm in frontal/parietal/temporal cortices and ≤2 cm in occipital cortex.</p>
</ol></li>
</ol>
<li>
<p>Small vessel ischemia</p>
<ol>
<li><p>Lacunar infarct is defined as an area of abnormal intensity seen on CT scan or on both T1 and T2 weighted MRI images in the basal ganglia, thalamus or deep white matter which is ≤1 cm in maximal diameter. A maximum of one lacune is allowed per scan.</p></li>
<li><p>Leukoariosis or leukoencephalopathy is regarded as an abnormality seen on T2 but not T1 weighted MRIs, or on CT. This is accepted if mild or moderate in extent, meaning involvement of less than 25% of cortical white matter. </p></li>
</ol>
<li><p>Miscellaneous</p>
<ol>
<li><p>Benign small extra-axial tumors (ie, meningiomas) are accepted if they do not contact or indent the brain parenchyma.</p></li>
<li><p>Small extra-axial arachnoid cysts are accepted if they do not indent or deform the brain parenchyma.</p></li>
</ol></li></li></p></td></tr><tr><td style="vertical-align: top; text-align: left"><p>06</p></td><td style="vertical-align: top; text-align: left"><p><p>Investigator has obtained informed consent signed by the patient (and/or legal representative) and by the caregiver.</p></p></td></tr><tr><td style="vertical-align: top; text-align: left"><p>07</p></td><td style="vertical-align: top; text-align: left"><p><p>Geographic proximity to investigator's site that allows adequate follow-up.</p></p></td></tr><tr><td style="vertical-align: top; text-align: left"><p>08</p></td><td style="vertical-align: top; text-align: left"><p><p>A reliable caregiver who is in frequent or daily contact with the patient and who will accompany the patient to the office and/or be available by telephone at designated times, will monitor administration of prescribed medications, and will be responsible for the overall care of the patient at home. The caregiver and the patient must be able to communicate in English and willing to comply with 26 weeks of transdermal therapy.</p></p></td></tr></table></div></div><div class=""><h2 id="section-5.4">5.4 Exclusion Criteria</h2><div><p>Patients may be excluded in the study for <strong>any</strong> of the following reasons:</p><table><tr><td style="vertical-align: top; text-align: left"><p>09</p></td><td style="vertical-align: top; text-align: left"><p><p>Persons who have previously completed or withdrawn from this study or any other study investigating xanomeline TTS or the oral formulation of xanomeline.</p></p></td></tr><tr><td style="vertical-align: top; text-align: left"><p>10</p></td><td style="vertical-align: top; text-align: left"><p><p>Use of any investigational agent or approved Alzheimer's therapeutic medication within 30 days prior to enrollment into the study.</p></p></td></tr><tr><td style="vertical-align: top; text-align: left"><p>11</p></td><td style="vertical-align: top; text-align: left"><p><p>Serious illness which required hospitalization within 3 months of screening.</p></p></td></tr><tr><td style="vertical-align: top; text-align: left"><p>12</p></td><td style="vertical-align: top; text-align: left"><p><p>Diagnosis of serious neurological conditions, including 
<ol type="a">
<li>a) Stroke or vascular dementia documented by clinical history and/or radiographic findings interpretable by the investigator as indicative of these disorders</li></ol></p>
<li><p>Seizure disorder other than simple childhood febrile seizures</p></li>
<li><p>Severe head trauma resulting in protracted loss of consciousness within the last 5 years, or multiple episodes of head trauma</p></li>
<li><p>Parkinson's disease</p></li>
<li><p>Multiple sclerosis</p></li>
<li><p>Amyotrophic lateral sclerosis</p></li>
<li><p>Myasthenia gravis.</p></li>
</p></td></tr><tr><td style="vertical-align: top; text-align: left"><p>13</p></td><td style="vertical-align: top; text-align: left"><p><p>Episode of depression meeting DSM-IV criteria within 3 months of screening.</p></p></td></tr><tr><td style="vertical-align: top; text-align: left"><p>14</p></td><td style="vertical-align: top; text-align: left"><p><p>A history within the last 5 years of the following:</p>
<ol type="a">
<li><p>a)  Schizophrenia</p></li>
<li><p>b)  Bipolar Disease</p></li>
<li><p>c)  Ethanol or psychoactive drug abuse or dependence. </p></li>
</ol></p></td></tr><tr><td style="vertical-align: top; text-align: left"><p>15</p></td><td style="vertical-align: top; text-align: left"><p><p>A history of syncope within the last 5 years.</p></p></td></tr><tr><td style="vertical-align: top; text-align: left"><p>16b</p></td><td style="vertical-align: top; text-align: left"><p><p>Evidence from ECG recording at screening of any of the following conditions :</p>
<ol type="a">
<li><p>a)  Left bundle branch block</p></li>
<li><p>b)  Bradycardia ≤50 beats per minute</p></li>
<li><p>c)  Sinus pauses &gt;2 seconds</p></li>
<li><p>d)  Second or third degree heart block unless treated with a pacemaker</p></li>
<li><p>e)  Wolff-Parkinson-White syndrome</p></li>
<li><p>f) Sustained supraventricular tachyarrhythmia including SVT≥10 sec, atrial fibrillation, atrial flutter.</p></li>
<li><p>g) Ventricular tachycardia at a rate of ≥120 beats per minute lasting</p></li>
<li><p>≥10 seconds.</p></li>
</ol></p></td></tr><tr><td style="vertical-align: top; text-align: left"><p>17</p></td><td style="vertical-align: top; text-align: left"><p><p>A history within the last 5 years of a serious cardiovascular disorder, including</p>
<ol type="a">
<li><p>a)  Clinically significant arrhythmia</p></li>
<li><p>b)  Symptomatic sick sinus syndrome not treated with a pacemaker</p></li>
<li><p>c)  Congestive heart failure refractory to treatment</p></li>
<li><p>d)  Angina except angina controlled with PRN nitroglycerin</p></li>
<li><p>e)  Resting heart rate &lt;50 or &gt;100 beats per minute, on physical exam</p></li>
<li><p>f)  Uncontrolled hypertension.</p></li>
</ol></p></td></tr><tr><td style="vertical-align: top; text-align: left"><p>18</p></td><td style="vertical-align: top; text-align: left"><p><p>A history within the last 5 years of a serious gastrointestinal disorder, including 
<ol type="a">
<li><p>Chronic peptic/duodenal/gastric/esophageal ulcer that are untreated or refractory to treatment</p></li>
<li><p>Symptomatic diverticular disease</p></li>
<li><p>Inflammatory bowel disease</p></li>
<li><p>Pancreatitis</p></li>
<li><p>Hepatitis</p></li>
<li><p>Cirrhosis of the liver.</p></li>
</ol></p></p></td></tr><tr><td style="vertical-align: top; text-align: left"><p>19</p></td><td style="vertical-align: top; text-align: left"><p><p>A history within the last 5 years of a serious endocrine disorder, including</p>
<ol type="a">
<li><p>Uncontrolled Insulin Dependent Diabetes Mellitus (IDDM)</p></li>
<li><p>Diabetic ketoacidosis</p></li>
<li><p>Untreated hyperthyroidism</p></li>
<li><p>Untreated hypothyroidism</p></li>
<li><p>Other untreated endocrinological disorder</p></li>
</ol></p></td></tr><tr><td style="vertical-align: top; text-align: left"><p>20</p></td><td style="vertical-align: top; text-align: left"><p><p> A history within the last 5 years of a serious respiratory disorder, including</p>
<ol type="a">
<li><p>Asthma with bronchospasm refractory to treatment</p></li>
<li><p>Decompensated chronic obstructive pulmonary disease.</p></li>
</ol></p></td></tr><tr><td style="vertical-align: top; text-align: left"><p>21</p></td><td style="vertical-align: top; text-align: left"><p><p>A history within the last 5 years of a serious genitourinary disorder, including</p>
<ol type="a">
<li><p>Renal failure</p></li>
<li><p>Uncontrolled urinary retention.</p></li>
</ol></p></td></tr><tr><td style="vertical-align: top; text-align: left"><p>22</p></td><td style="vertical-align: top; text-align: left"><p><p>A history within the last 5 years of a serious rheumatologic disorder, including</p>
<ol type="a">
<li><p>Lupus</p></li>
<li><p>Temporal arteritis</p></li>
<li><p>Severe rheumatoid arthritis.</p></li>
</ol></p></td></tr><tr><td style="vertical-align: top; text-align: left"><p>23</p></td><td style="vertical-align: top; text-align: left"><p><p>A known history of human immunodeficiency virus (HIV) within the last 5 years.</p></p></td></tr><tr><td style="vertical-align: top; text-align: left"><p>24</p></td><td style="vertical-align: top; text-align: left"><p><p>A history within the last 5 years of a serious infectious disease including</p>
<ol type="a">
<li><p>a)  Neurosyphilis</p></li>
<li><p>b)  Meningitis</p></li>
<li><p>c)  Encephalitis.</p></li>
</ol></p></td></tr><tr><td style="vertical-align: top; text-align: left"><p>25</p></td><td style="vertical-align: top; text-align: left"><p><p>A history within the last 5 years of a primary or recurrent malignant disease with the exception of resected cutaneous squamous cell carcinoma in situ, basal cell carcinoma, cervical carcinoma in situ, or in situ prostate cancer with a normal PSA postresection.</p></p></td></tr><tr><td style="vertical-align: top; text-align: left"><p>26</p></td><td style="vertical-align: top; text-align: left"><p><p>Visual, hearing, or communication disabilities impairing the ability to participate in the study; (for example, inability to speak or understand English, illiteracy).</p></p></td></tr><tr><td style="vertical-align: top; text-align: left"><p>27b</p></td><td style="vertical-align: top; text-align: left"><p><p>[Laboratory test values exceeding the Lilly Reference Range III for the patient's age in any of the following analytes: ↑ creatinine, ↑ total bilirubin, ↑ SGOT, ↑ SGPT, ↑ alkaline phosphatase, ↑ GGT, ↑↓ hemoglobin, ↑↓ white blood cell count, ↑↓ platelet count, ↑↓ serum sodium, potassium, or calcium.</p>
<p>If values exceed these laboratory reference ranges, clinical significance will be judged by the monitoring physicians. If the monitoring physician determines that the deviation from the reference range is not clinically significant, the patient may be included in the study. This decision will be documented.</p></p></td></tr><tr><td style="vertical-align: top; text-align: left"><p>28b</p></td><td style="vertical-align: top; text-align: left"><p><p>Central laboratory test values below reference range for folate, and Vitamin B 12 , and outside reference range for thyroid function tests.</p>
<ol type="a">
<li><p>Folate reference range 2.0 to 25.0 ng/mL. Patients will be allowed to enroll if their folate levels are above the upper end of the range if patients are taking vitamin supplements.</p>
<li><p>Vitamin B 12 reference range 130 to 900 pg/mL. Patients will be 
allowed to enroll if their B 12 levels are above the upper reference 
range if patients are taking oral vitamin supplements.</p>
<li><p>Thyroid functions</p>
<ol type="i">
<li><p>Thyroid Uptake reference range 25 to 38%. Patients will be allowed to enroll with results of 23 to 51% provided the remainder of the thyroid profile is normal and there are no clinical signs or symptoms of thyroid abnormality.</p></li>
<li><p>TSH reference range 0.32 to 5.0. Patients will be allowed to enroll with results of 0.03 to 6.2 if patients are taking stable doses of exogenous thyroid supplements, with normal free thyroid index, and show no clinical signs or symptoms of thyroid abnormality.</p></li>
<li><p>Total T4 reference range 4.5 to 12.5. Patients will be allowed to enroll with results of 4.1 to 13.4 if patients are taking stable doses of exogenous thyroid hormone, with normal free thyroid index, and show no clinical signs or symptoms of thyroid 
abnormality.</p></li>
<li><p>Free Thyroid Index reference range 1.1 to 4.6.</p></li>
</ol>
</li></li></li></ol>
<p>Treatment with the following medications within the specified washout periods prior to enrollment and during the study:</p>
<ol type="a">
<li><p>Anticonvulsants including but not limited to 
<table class="table">
<tr><td>Depakote® (valproic acid) </td><td>2 weeks </td></tr>
<tr><td>Dilantin® (phenytoin)</td><td>2 weeks</td></tr>
<tr><td>Felbatol® (felbamate)</td><td>1 month</td></tr>
<tr><td>Klonopin® (clonazepam)</td><td>2 weeks</td></tr>
<tr><td>Lamictal® (lamotrigine)</td><td>2 weeks </td></tr>
<tr><td>Mysoline® (primidone)</td><td>1 month</td></tr>
<tr><td>Neurontin® (gabapentin)</td><td>2 weeks</td></tr>
<tr><td>Phenobarbitol</td><td>1 month</td></tr>
<tr><td>Tegretol® (carbamazepine)</td><td>2 weeks</td></tr>
</table>
</p></li>
<li><p>Alpha receptor blockers including but not limited to 
<table class="table">
<tr><td>Aldomet® (methyldopa) </td><td>2 weeks </td></tr>
<tr><td>Cardura® (doxazosin) </td><td>2 weeks </td></tr>
<tr><td>Catapres® (clonidine) </td><td>2 weeks </td></tr>
<tr><td>Hytrin® (terazosin) </td><td>2 weeks </td></tr>
<tr><td>Minipress® (prazosin)</td><td> 2 weeks</td></tr>
<tr><td>Tenex® (guanfacine)</td><td> 2 weeks </td></tr>
<tr><td>Wytensin® (guanabenz) </td><td>2 weeks</td></tr>
</table>
<p><b>The use of low doses (2 mg daily) of either Hytrin</b>® <b>or Cardura</b>® <b>for relief of urinary retention for patients with prostatic hypertrophy will be considered on a case-by-case basis provided blood pressure is stable and the medication has not had demonstrable effect on dementia symptoms in the opinion of the treating physician. Contact CRO medical monitor.</b></p>
<li><p>Calcium channel blockers that are CNS active including but not 
limited to 
<table class="table">
<tr><td>Calan® , Isoptin® , Verelan® (verapamil) </td><td>2 weeks 
  <tr><td>Cardizem® (diltiazem) </td><td>2 weeks </td></tr>
<tr><td>Nimotop® (nimodipine) </td><td>2 weeks </td></tr>
<tr><td>Adalat® , Procardia XL® (nifedipine) </td><td>2 weeks</td></tr>
</td></tr></table>
<p><b>Cardene</b>® <b>(nicardipine), Norvasc</b>® <b>, (amlodipine), and DynaCirc</b>® <b>(isradipine) will be allowed during the study. If a patient is taking an excluded calcium channel blocker and is changed to an equivalent dose of an allowed calcium channel blocker, enrollment may proceed in as little as 24 hours though 1 week is preferred when possible.</b></p>
<li><p>Beta blockers including but not limited to 
<table class="table">
<tr><td>Betapace® (sotalol) </td><td>2 weeks</td></tr>
<tr><td>Inderal® (propranolol) </td><td>2 weeks</td></tr>
<tr><td>Lopressor® , Toprol XL® (metoprolol) </td><td>2 weeks</td></tr>
<tr><td>Corgard® (nadolol) </td><td>2 weeks</td></tr>
<tr><td>Sectral® (acebutolol)</td><td>2 weeks</td></tr>
<tr><td>Tenormin® (atenolol) </td><td>2 weeks</td></tr>
<tr><td>Visken® (pindolol)</td><td>2 weeks</td></tr>
</table>
<p><b>Beta blocker eye drops for glaucoma will be considered on a case-by-case basis. Call medical monitor.</b></p>
<li><p>Beta sympathomimetics (unless inhaled) including but not limited to 
<table class="table">
<tr><td>Alupent® tablets (metaproterenol) </td><td>2 weeks </td></tr>
<tr><td>Brethine® tablets (terbutaline) </td><td>2 weeks </td></tr>
<tr><td>Dopamine </td><td>2 weeks 
  <tr><td>Proventil Repetabs® , Ventolin® tablets (albuterol tablets) </td><td>2 weeks</td></tr>
</td></tr></table>
<li>Parasympathomimetics (cholinergics) (unless opthalmic) including but not limited to 
<table class="table">
<tr><td>Antilirium® (physostigmine) </td><td>1 month</td></tr>
<tr><td>Aricept® (donepezil) </td><td>1 month</td></tr>
<tr><td>Cognex® (tacrine) </td><td>1 month</td></tr>
<tr><td>Mestinon® (pyridostigmine) </td><td>1 week</td></tr>
<tr><td>Reglan® (metoclopramide)</td><td> 2 weeks</td></tr>
<tr><td>Urecholine® , Duvoid (bethanechol) </td><td>2 weeks</td></tr>
</table>
<b>Cholinergic eye drops for treatment of glaucoma will be allowed during the study on a case-by-case basis. Please contact the CRO medical monitor.</b></li></p>
<li><p>Muscle relaxants-centrally active including but not limited to 
<table class="table">
<tr><td>Equanil® (meprobamate) </td><td>2 weeks</td></tr>
<tr><td>Flexeril® (cyclobenzaprine)</td><td> 2 weeks </td></tr>
<tr><td>Lioresal® (baclofen) </td><td>2 weeks </td></tr>
<tr><td>Norflex® (orphenadrine) </td><td>2 weeks</td></tr>
<tr><td>Parafon Forte® (chlorzoxazone)</td><td> 2 weeks</td></tr>
<tr><td>Robaxin® (methocarbamol) </td><td>2 weeks</td></tr>
<tr><td>Skelaxin® (metaxalone) </td><td>2 weeks</td></tr>
<tr><td>Soma® (carisoprodol) </td><td>2 weeks</td></tr>
</table>
<li><p>Monamine oxidase inhibitors (MAOI) including but not limited to 
<table class="table">
<tr><td>Eldepryl® (selegiline)</td><td>1 month</td></tr>
<tr><td>Nardil® (phenelzine) </td><td>1 month</td></tr>
<tr><td>Parnate® (tranylcypromine) </td><td>1 month</td></tr>
</table>
<li><p>Parasympatholytics including but not limited to 
<table class="table">
<tr><td>Antivert® , Bonine® , Dramamine II® (meclizine)</td><td>3 days </td></tr>
<tr><td>Artane® (trihexyphenidyl)</td><td>2 weeks </td></tr>
<tr><td>Bellergal-S® (alkaloids of belladonna and ergotamine) </td><td>2 weeks </td></tr>
<tr><td>Bentyl® (dicyclomine) </td><td>3 days </td></tr>
<tr><td>Cogentin® (benztropine) </td><td>2 weeks </td></tr>
<tr><td>Cystospaz® , Levsin® , Levsinex® (hyoscyamine)</td><td>2 weeks </td></tr>
<tr><td>Ditropan® (oxybutynin) </td><td>2 weeks</td></tr>
<tr><td>Donnatal® , Hyosophen® (atropine, scopolamine, hyoscyamine and phenobarbitol) </td><td>1 month </td></tr>
<tr><td>Dramamine® (dimenhydrinate)</td><td> 3 days </td></tr>
<tr><td>Lomotil® , Lonox® (atropine, diphenoxylate) </td><td>2 weeks </td></tr>
<tr><td>Pro-Banthine® (propantheline) </td><td>2 weeks</td></tr>
<tr><td>Robinul® (glycopyrrolate) </td><td>3 days </td></tr>
<tr><td>Tigan® (trimethobenzamide) </td><td>3 days </td></tr>
<tr><td>Transderm-Scop® (scopolamine) </td><td>2 weeks </td></tr>
<tr><td>Urispas® (flavoxate) 2 weeks </td></tr>
</table>
<li><p>Antidepressants including but not limited to 
<table class="table">
<tr><td>Anafranil® (clomipramine)</td><td> 1 month</td>
<tr><td>Asendin® (amoxapine)</td><td> 1 month</td>
<tr><td>Desyrel® (trazodone)</td><td> 1 month</td>
<tr><td>Effexor® (venlafaxine) </td><td> 1 month</td>
<tr><td>Elavil® (amitriptyline)</td><td> 1 month</td>
<tr><td>Ludiomil® (maprotiline)</td><td> 1 month</td>
<tr><td>Norpramin® (desipramine)</td><td> 1 month</td>
<tr><td>Pamelor® , Aventyl® (nortriptyline)</td><td> 1 month</td>
<tr><td>Paxil® (paroxetine)</td><td> 1 month</td>
<tr><td>Prozac® (fluoxetine</td><td> 1 month</td>
<tr><td>Remeron® (mirtazapine)</td><td> 1 month</td>
<tr><td>Serzone® (nefazodone) </td><td> 1 month</td>
<tr><td>Sinequan® (doxepin)</td><td> 1 month</td>
<tr><td>Tofranil® (imipramine)</td><td> 1 month</td>
<tr><td>Vivactil® (protriptyline)</td><td> 1 month</td>
<tr><td>Wellbutrin® (bupropion)</td><td> 1 month</td>
<tr><td>Zoloft® (sertraline)</td><td> 1 month</td>
</tr></tr></tr></tr></tr></tr></tr></tr></tr></tr></tr></tr></tr></tr></tr></tr></tr></table>
<li><p>Systemic corticosteroids including but not limited to 
<table class="table">
<tr><td>Cortisone</td><td>2 weeks</td><td>
<tr><td>Decadron® (dexamethasone)</td><td>2 weeks</td><td>
<tr><td>Depo-Medrol® (methylprednisolone)</td><td>1 month</td><td>
<tr><td>Prednisone</td><td>2 weeks</td><td></td></tr></td></tr></td></tr></td></tr></table>
<li><p>Xanthine derivatives including but not limited to 
<table class="table">
<tr><td>Aminophylline</td><td>2 weeks</td><td>
<tr><td>Fioricet® , Esgic® , Phrenilin Forte® (caffeine, 
butalbital)</td><td>3 days</td><td>
<tr><td>Theo-Dur® (theophylline)</td><td>2 weeks</td><td>
<tr><td>Wigraine® , Cafergot® (caffeine, ergotamine)</td><td>3 days</td><td>
</td></tr></td></tr></td></tr></td></tr></table>
<li><p>Histamine (H2 ) antagonists including but not limited to 
<table class="table">
<tr><td>Axid® (nizatidine)</td><td>1 week</td></tr>
<tr><td>Pepcid® (famotidine)</td><td>1 week</td></tr>
<tr><td>Tagamet® (cimetidine)</td><td>1 week</td></tr>
<tr><td>Zantac® (ranitidine)</td><td>1 week</td></tr>
</table>
<p><b>If an H 2 antagonist is needed by the patient, Axid</b>® <b>will be</b>
<b>allowed on a case-by-case basis. Please consult CRO</b>
<b>medical monitor.</b></p>
<li><p>Narcotic Analgesics including but not limited to 
<table class="table">
<tr><td>Darvocet-N 100® , (propoxyphene)</td><td>1 week </td></tr>
<tr><td>Demerol® (meperidine)</td><td>1 week </td></tr>
<tr><td>Dilaudid® (hydromorphone)</td><td>1 week </td></tr>
<tr><td>Duragesic® (fentanyl)</td><td>1 week </td></tr>
<tr><td>MS Contin® , Roxanol® , Oramorph® 
(morphine) </td><td>1 week </td></tr>
<tr><td>Percocet® , Roxicet® (oxycodone with 
acetaminophen)</td><td>3 days </td></tr>
<tr><td>Percodan® , Roxiprin</td><td>1 week</td></tr>
<tr><td>Stadol® (butorphanol)</td><td>1 week </td></tr>
<tr><td>Talacen® (pentazocine)</td><td>1 week </td></tr>
<tr><td>Tylenol #2® , #3® , #4® (codeine and acetaminophen) </td><td>3 days </td></tr>
<tr><td>Tylox® , Roxilox® (oxycodone)</td><td>3 days </td></tr>
<tr><td>Vicodin® , Lorcet® (hydrocodone)</td><td>1 week</td></tr>
</table>
<p><b>Percocet (oxycodone with acetaminophen) and Tylenol</b>® <b>with codeine #2, #3, #4 (acetaminophen + codeine) ARE allowed in the month prior to enrollment, but are not permitted in the 3 days prior to enrollment.</b></p>
<li><p>Neuroleptics (antipsychotics) including but not limited to 
<table class="table">
<tr><td>Clozaril® (clozapine)</td><td>2 weeks</td></tr>
<tr><td>Haldol® (haloperidol)</td><td>2 weeks</td></tr>
<tr><td>Loxitane® (loxapine)</td><td>2 weeks</td></tr>
<tr><td>Mellaril® (thioridazine)</td><td>2 weeks</td></tr>
<tr><td>Moban® (molindone)</td><td>2 weeks</td></tr>
<tr><td>Navane® (thiothixene)</td><td>2 weeks</td></tr>
<tr><td>Orap® (pimozide)</td><td>2 weeks</td></tr>
<tr><td>Prolixin® (fluphenazine)</td><td>1 month</td></tr>
<tr><td>Risperdal® (risperidone)</td><td>2 weeks</td></tr>
<tr><td>Stelazine® (trifluoperazine)</td><td>2 weeks</td></tr>
<tr><td>Thorazine® (chlorpromazine)</td><td>2 weeks</td></tr>
<tr><td>Trilafon® (perphenazine)</td><td>2 weeks</td></tr>
<tr><td>Serentil® (mesoridazine)</td><td>2 weeks</td></tr>
</table>
<p><b>The use of neuroleptics on a daily basis must be discontinued 2 to 4 weeks prior to enrollment. The use of neuroleptics on an as-needed basis is allowable during the screening period, but the last dose must be at least 7 days prior to enrollment.</b></p>
<li><p>Antianxiety agents including but not limited to 
<table class="table">
<tr><td>Atarax® (hydroxyzine)</td><td>2 weeks</td></tr>
<tr><td>BuSpar® (buspirone)</td><td>2 weeks</td></tr>
<tr><td>Librium® (chlordiazepoxide)</td><td>2 weeks</td></tr>
<tr><td>Serax® (oxazepam)</td><td>2 weeks</td></tr>
<tr><td>Tranxene® (clorazepate)</td><td>2 weeks</td></tr>
<tr><td>Valium® (diazepam)</td><td>2 weeks</td></tr>
<tr><td>Vistaril® (hydroxyzine pamoate)</td><td>2 weeks</td></tr>
<tr><td>Xanax® (alprazolam)</td><td>2 weeks</td></tr>
</table>
<p><b>Ativan</b>® <b>(lorazepam) should be discontinued on a daily basis 2 weeks</b></p>
<p><b>prior to enrollment. It may be used on an as-needed basis during the screening period, but is not permitted in the 24 hours prior to enrollment.</b></p>
<li><p>Hypnotics/Sedatives including but not limited to 
<table class="table">
<tr><td>Ambien® (zolpidem)</td><td> 3 days </td></tr>
<tr><td>Dalmane® (flurazepam)</td><td> 3 days </td></tr>
<tr><td>Doral® (quazepam)</td><td> 3 days </td></tr>
<tr><td>Halcion® (triazolam)</td><td> 3 days </td></tr>
<tr><td>Nembutal® </td><td>2 weeks </td></tr>
<tr><td>ProSom® (estazolam)</td><td> 3 days </td></tr>
<tr><td>Restoril® (temazepam)</td><td> 3 days </td></tr>
<tr><td>Seconal®</td><td> 2 weeks</td></tr>
</table>
<p><b>Chloral Hydrate is allowed on an as-needed basis during</b>
<b>screening, but is not permitted in the 24 hours prior to</b>
<b>enrollment.</b></p>
<li><p>Histamine (H1 ) antagonists including but not limited to 
<table class="table">
<tr><td>Actifed® , Actifed Plus® (triprolidine) Benadryl® , Unisom® , Tylenol P.M.® </td><td>3 days </td></tr>
<tr><td>(diphenhydramine)</td><td>3 days</td></tr>
<tr><td>Compazine® (prochlorperazine)</td><td>3 days</td></tr>
<tr><td>Contac® , Coricidin D® , Sinutab® , Novahistine® , Alka Seltzer Plus® , Naldecon® , Sudafed Plus® , Tylenol Cold® , Tylenol Cold and Flu® (chlorpheniramine)</td><td>3 days</td>
<tr><td>Dimetapp® (brompheniramine)</td><td>3 days</td>
<tr><td>Drixoral® (dexbrompheniramine)</td><td>3 days</td>
<tr><td>Hismanal® (astemizole)</td><td>1 week</td>
<tr><td>Phenergan® (promethazine)</td><td>3 days</td>
<tr><td>Seldane® (terfenadine)</td><td>1 week</td>
<tr><td>Tavist® (clemastine fumarate)</td><td>3 days</td>
<tr><td>Zyrtec® (cetrizine) </td><td>1 week</td>
</tr></tr></tr></tr></tr></tr></tr></tr></table>
<p><b>Allegra</b>® <b>(fexofenadine hydrochloride) or Claritin</b>® <b>(loratadine) may be taken on as-needed basis during screening but must be discontinued within 24 hours of enrollment.</b></p>
<li><p>Stimulants including but not limited to 
<table class="table">
<tr><td>Cylert® (pemoline) </td><td>1 month</td></tr>
<tr><td>Ritalin® (methylphenidate)</td><td>1 month</td></tr>
</table>
<li><p>Antiarrhythmics including but not limited to the following 
<table class="table">
<tr><td>Adenocard® (adenosine) </td></tr>
<tr><td>Cordarone® (amiodarone) </td></tr>
<tr><td>Ethmozine® (moricizine) </td></tr>
<tr><td>Mexitil® (mexiletine) </td></tr>
<tr><td>Norpace® (disopyramide) </td></tr>
<tr><td>Procan® (procainamide) </td></tr>
<tr><td>Quinaglute® (quinidine) </td></tr>
<tr><td>Rythmol® (propafenone) </td></tr>
<tr><td>Tambocor® (flecainide) </td></tr>
<tr><td>Tonocard® (tocainide)</td></tr>
</table>
<p><b>Requirement of these drugs for control of cardiac arrhythmia indicates that the patient should be excluded from the study. If discontinuation of an antiarrhythmic is considered, please discuss case with CRO medical monitor.</b></p>
<li><p>Miscellaneous drugs including but not limited to 
<table class="table">
<tr><td>Coenzyme Q</td><td>2 weeks </td></tr>
<tr><td>Eskalith® , Lithobid® (lithium)</td><td>2 weeks </td></tr>
<tr><td>Ginkgo biloba</td><td>1 week</td></tr>
<tr><td>Lecithin </td><td>1 week</td></tr>
<tr><td>Lecithin </td><td>1 week </td></tr>
<tr><td>Lupron</td><td>2 weeks </td></tr>
<tr><td>Tamoxifen</td><td>1 month</td></tr>
</table>
<li><p>Estrogen supplements are permitted during the study, but dosage must be stable for at least 3 months prior to enrollment.</p></li></p></li></p></li></p></li></p></li></p></li></p></li></p></li></p></li></p></li></p></li></p></li></p></li></p></li></p></li></p></li></li></p></li></p></li></p></li></ol></p></td></tr><tr><td style="vertical-align: top; text-align: left"><p>29b</p></td><td style="vertical-align: top; text-align: left"><p><p>Positive syphilis screening.</p>
<p>Positive syphilis screening. As determined by positive RPR followed up by confirmatory FTA-Abs. Confirmed patients are excluded unless there is a documented medical history of an alternative disease (for example, yaws) which caused the lab abnormality.</p></p></td></tr><tr><td style="vertical-align: top; text-align: left"><p>30b</p></td><td style="vertical-align: top; text-align: left"><p><p>Glycosylated hemoglobin (A1C). Required only on patients with known diabetes mellitus or random blood sugar &gt;200 on screening labs. Patients will be excluded if levels are &gt;9.5%</p></p></td></tr><tr><td style="vertical-align: top; text-align: left"><p>31b</p></td><td style="vertical-align: top; text-align: left"><p><p>Glycosylated hemoglobin (A1C). Required only on patients with known diabetes mellitus or random blood sugar &gt;200 on screening labs. Patients will be excluded if levels are &gt;9.5%</p></p></td></tr></table></div></div><div class=""><h2 id="section-5.5">5.5 Lifestyle Considerations</h2><div></div><div class=""><h3 id="section-5.5.1">5.5.1 Meals and Dietary Restrictions</h3><div></div></div><div class=""><h3 id="section-5.5.2">5.5.2 Caffeine, Alcohol, Tobacco, and Other Habits</h3><div><p>Not applicable</p></div></div><div class=""><h3 id="section-5.5.3">5.5.3 Physical Activity</h3><div></div></div><div class=""><h3 id="section-5.5.4">5.5.4 Other Activity</h3><div></div></div></div><div class=""><h2 id="section-5.6">5.6 Screen Failures</h2><div></div></div></div><div class="page"><h1 id="section-6">6 TRIAL INTERVENTION AND CONCOMITANT THERAPY</h1><div></div><div class=""><h2 id="section-6.1">6.1 Description of Trial Intervention</h2><div></div></div><div class=""><h2 id="section-6.2">6.2 Rationale for Trial Intervention</h2><div></div></div><div class=""><h2 id="section-6.3">6.3 Dosing and Administration</h2><div></div><div class=""><h3 id="section-6.3.1">6.3.1 Trial Intervention Dose Modification</h3><div></div></div></div><div class=""><h2 id="section-6.4">6.4 Treatment of Overdose</h2><div></div></div><div class=""><h2 id="section-6.5">6.5 Preparation, Handling, Storage and Accountability</h2><div></div><div class=""><h3 id="section-6.5.1">6.5.1 Preparation of Trial Intervention</h3><div></div></div><div class=""><h3 id="section-6.5.2">6.5.2 Handling and Storage of Trial Intervention</h3><div></div></div><div class=""><h3 id="section-6.5.3">6.5.3 Accountability of Trial Intervention</h3><div></div></div></div><div class=""><h2 id="section-6.6">6.6 Participant Assignment, Randomisation and Blinding</h2><div></div><div class=""><h3 id="section-6.6.1">6.6.1 Participant Assignment</h3><div></div></div><div class=""><h3 id="section-6.6.2">6.6.2 Randomisation</h3><div></div></div><div class=""><h3 id="section-6.6.3">6.6.3 Blinding and Unblinding</h3><div><p>The study will be double-blind. To further preserve the blinding of the study, only a minimum number of Lilly and CRO personnel will see the randomization table and codes before the study is complete.</p>
<p>Emergency codes generated by a computer drug-labeling system will be available to the investigator. These codes, which reveal the patients treatment group, may be opened during the study only if the choice of follow-up treatment depends on the patient’s therapy assignment.</p>
<p>The investigator should make every effort to contact the clinical research physician prior to unblinding a patient’s therapy assignment. If a patient’s therapy assignment is unblinded, Lilly must be notified immediately by telephone. After the study, the investigator must return all sealed and any opened codes.</p></div></div></div><div class=""><h2 id="section-6.7">6.7 Trial Intervention Compliance</h2><div></div></div><div class=""><h2 id="section-6.8">6.8 Concomitant Therapy</h2><div></div><div class=""><h3 id="section-6.8.1">6.8.1 Prohibited Concomitant Therapy</h3><div></div></div><div class=""><h3 id="section-6.8.2">6.8.2 Permitted Concomitant Therapy</h3><div></div></div><div class=""><h3 id="section-6.8.3">6.8.3 Rescue Therapy</h3><div></div></div><div class=""><h3 id="section-6.8.4">6.8.4 Other Therapy</h3><div></div></div></div></div><div class="page"><h1 id="section-7">7 DISCONTINUATION OF TRIAL INTERVENTION AND PARTICIPANT WITHDRAWAL FROM TRIAL</h1><div></div><div class=""><h2 id="section-7.1">7.1 Discontinuation of Trial Intervention</h2><div></div><div class=""><h3 id="section-7.1.1">7.1.1 Criteria for Permanent Discontinuation of Trial Intervention</h3><div></div></div><div class=""><h3 id="section-7.1.2">7.1.2 Temporary Discontinuation or Interruption of Trial Intervention</h3><div></div></div><div class=""><h3 id="section-7.1.3">7.1.3 Rechallenge</h3><div></div></div></div><div class=""><h2 id="section-7.2">7.2 Participant Withdrawal from the Trial</h2><div></div></div><div class=""><h2 id="section-7.3">7.3 Lost to Follow-Up</h2><div></div></div><div class=""><h2 id="section-7.4">7.4 Trial Stopping Rules</h2><div></div></div></div><div class="page"><h1 id="section-8">8 TRIAL ASSESSMENTS AND PROCEDURES</h1><div></div><div class=""><h2 id="section-8.1">8.1 Screening/Baseline Assessments and Procedures</h2><div></div></div><div class=""><h2 id="section-8.2">8.2 Efficacy Assessments and Procedures</h2><div></div></div><div class=""><h2 id="section-8.3">8.3 Safety Assessments and Procedures</h2><div></div><div class=""><h3 id="section-8.3.1">8.3.1 Physical Examination</h3><div></div></div><div class=""><h3 id="section-8.3.2">8.3.2 Vital Signs</h3><div></div></div><div class=""><h3 id="section-8.3.3">8.3.3 Electrocardiograms</h3><div></div></div><div class=""><h3 id="section-8.3.4">8.3.4 Clinical Laboratory Assessments</h3><div></div></div><div class=""><h3 id="section-8.3.5">8.3.5 Suicidal Ideation and Behaviour Risk Monitoring</h3><div></div></div></div><div class=""><h2 id="section-8.4">8.4 Adverse Events and Serious Adverse Events</h2><div></div><div class=""><h3 id="section-8.4.1">8.4.1 Definitions of AE and SAE</h3><div></div></div><div class=""><h3 id="section-8.4.2">8.4.2 Time Period and Frequency for Collecting AE and SAE Information</h3><div></div></div><div class=""><h3 id="section-8.4.3">8.4.3 Identifying AEs and SAEs</h3><div></div></div><div class=""><h3 id="section-8.4.4">8.4.4 Recording of AEs and SAEs</h3><div></div></div><div class=""><h3 id="section-8.4.5">8.4.5 Follow-up of AEs and SAEs</h3><div></div></div><div class=""><h3 id="section-8.4.6">8.4.6 Reporting of SAEs</h3><div></div></div><div class=""><h3 id="section-8.4.7">8.4.7 Regulatory Reporting Requirements for SAEs</h3><div></div></div><div class=""><h3 id="section-8.4.8">8.4.8 Serious and Unexpected Adverse Reaction Reporting</h3><div></div></div><div class=""><h3 id="section-8.4.9">8.4.9 Adverse Events of Special Interest</h3><div></div></div><div class=""><h3 id="section-8.4.10">8.4.10 Disease-related Events or Outcomes Not Qualifying as AEs or SAEs</h3><div></div></div></div><div class=""><h2 id="section-8.5">8.5 Pregnancy and Postpartum Information</h2><div></div><div class=""><h3 id="section-8.5.1">8.5.1 Participants Who Become Pregnant During the Trial</h3><div></div></div><div class=""><h3 id="section-8.5.2">8.5.2 Participants Whose Partners Become Pregnant</h3><div></div></div></div><div class=""><h2 id="section-8.6">8.6 Medical Device Product Complaints for Drug/Device Combination Products</h2><div></div><div class=""><h3 id="section-8.6.1">8.6.1 Definition of Medical Device Product Complaints</h3><div></div></div><div class=""><h3 id="section-8.6.2">8.6.2 Recording of Medical Device Product Complaints</h3><div></div></div><div class=""><h3 id="section-8.6.3">8.6.3 Time Period and Frequency for Collecting Medical Device Product Complaints .</h3><div></div></div><div class=""><h3 id="section-8.6.4">8.6.4 Follow-Up of Medical Device Product Complaints</h3><div></div></div><div class=""><h3 id="section-8.6.5">8.6.5 Regulatory Reporting Requirements for Medical Device Product Complaints</h3><div></div></div></div><div class=""><h2 id="section-8.7">8.7 Pharmacokinetics</h2><div></div></div><div class=""><h2 id="section-8.8">8.8 Genetics</h2><div></div></div><div class=""><h2 id="section-8.9">8.9 Biomarkers</h2><div></div></div><div class=""><h2 id="section-8.1">8.1 Immunogenicity Assessments</h2><div></div><div class=""><h3 id="section-8.1.1">8.1.1 Medical Resource Utilisation and Health Economics</h3><div></div></div></div></div><div class="page"><h1 id="section-9">9 STATISTICAL CONSIDERATIONS</h1><div></div><div class=""><h2 id="section-9.1">9.1 Analysis Sets</h2><div></div></div><div class=""><h2 id="section-9.2">9.2 Analyses Supporting Primary Objective(s)</h2><div></div><div class=""><h3 id="section-9.2.1">9.2.1 Statistical Model, Hypothesis, and Method of Analysis</h3><div></div></div><div class=""><h3 id="section-9.2.2">9.2.2 Handling of Intercurrent Events of Primary Estimand(s)</h3><div></div></div><div class=""><h3 id="section-9.2.3">9.2.3 Handling of Missing Data</h3><div></div></div><div class=""><h3 id="section-9.2.4">9.2.4 Sensitivity Analysis</h3><div></div></div><div class=""><h3 id="section-9.2.5">9.2.5 Supplementary Analysis</h3><div></div></div></div><div class=""><h2 id="section-9.3">9.3 Analysis Supporting Secondary Objective(s)</h2><div></div></div><div class=""><h2 id="section-9.4">9.4 Analysis of Exploratory Objective(s)</h2><div></div></div><div class=""><h2 id="section-9.5">9.5 Safety Analyses</h2><div></div></div><div class=""><h2 id="section-9.6">9.6 Other Analyses</h2><div></div></div><div class=""><h2 id="section-9.7">9.7 Interim Analyses</h2><div></div></div><div class=""><h2 id="section-9.8">9.8 Sample Size Determination</h2><div></div></div><div class=""><h2 id="section-9.9">9.9 Protocol Deviations</h2><div></div></div></div><div class="page"><h1 id="section-10">10 GENERAL CONSIDERATIONS: REGULATORY, ETHICAL, AND TRIAL OVERSIGHT</h1><div></div><div class=""><h2 id="section-10.1">10.1 Regulatory and Ethical Considerations</h2><div></div></div><div class=""><h2 id="section-10.2">10.2 Committees</h2><div></div></div><div class=""><h2 id="section-10.3">10.3 Informed Consent Process</h2><div></div></div><div class=""><h2 id="section-10.4">10.4 Data Protection</h2><div></div></div><div class=""><h2 id="section-10.5">10.5 Early Site Closure or Trial Termination</h2><div></div></div></div><div class="page"><h1 id="section-11">11 GENERAL CONSIDERATIONS: RISK MANAGEMENT AND QUALITY ASSURANCE</h1><div></div><div class=""><h2 id="section-11.1">11.1 Quality Tolerance Limits</h2><div></div></div><div class=""><h2 id="section-11.2">11.2 Data Quality Assurance</h2><div></div></div><div class=""><h2 id="section-11.3">11.3 Source Data</h2><div></div></div></div><div class="page"><h1 id="section-12">12 APPENDIX: ADVERSE EVENTS AND SERIOUS ADVERSE EVENTS - DEFINITIONS, SEVERITY, AND CAUSALITY</h1><div></div><div class=""><h2 id="section-12.1">12.1 Further Details and Clarifications on the AE Definition</h2><div></div></div><div class=""><h2 id="section-12.2">12.2 Further Details and Clarifications on the SAE Definition</h2><div></div></div><div class=""><h2 id="section-12.3">12.3 Severity</h2><div></div></div><div class=""><h2 id="section-12.4">12.4 Causality</h2><div></div></div></div><div class="page"><h1 id="section-13">13 APPENDIX: DEFINITIONS AND SUPPORTING OPERATIONAL DETAILS</h1><div></div><div class=""><h2 id="section-13.1">13.1 Contraception and Pregnancy Testing</h2><div></div><div class=""><h3 id="section-13.1.1">13.1.1 Definitions Related to Childbearing Potential</h3><div></div></div><div class=""><h3 id="section-13.1.2">13.1.2 Contraception</h3><div></div></div><div class=""><h3 id="section-13.1.3">13.1.3 Pregnancy Testing</h3><div></div></div></div><div class=""><h2 id="section-13.2">13.2 Clinical Laboratory Tests</h2><div></div></div><div class=""><h2 id="section-13.3">13.3 Country/Region-Specific Differences</h2><div></div></div><div class=""><h2 id="section-13.4">13.4 Prior Protocol Amendments</h2><div></div></div></div><div class="page"><h1 id="section-14">14 APPENDIX: GLOSSARY OF TERMS</h1><div></div></div><div class="page"><h1 id="section-15">15 APPENDIX: REFERENCES</h1><div></div></div></body></html>